{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:00:12Z","timestamp":1770656412426,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5428,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.nurt.2008.09.001","type":"journal-article","created":{"date-parts":[[2008,10,4]],"date-time":"2008-10-04T15:11:21Z","timestamp":1223133081000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of Neuromuscular Channelopathies: Current Concepts and Future Prospects"],"prefix":"10.1016","volume":"5","author":[{"given":"James C.","family":"Cleland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.09.001_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mus.20295","article-title":"Phenotypic variability in myotonia congenita","volume":"32","author":"Colding-J\u00f8rgensen","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib2","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI25525","article-title":"Muscle channelopathies and critical points in functional and genetic studies","volume":"115","author":"Jurkatt-Rott","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nurt.2008.09.001_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/mus.20928","article-title":"Paradoxical depolarization of BA2+- treated muscle exposed to low extracellular K+: Insights into resting potential abnormalities in hypokalemic paralysis","volume":"37","author":"Struyk","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib4","series-title":"Neurobiology of Disease","first-page":"319","article-title":"Channelopathies of the nervous system","author":"Cleland","year":"2007"},{"key":"10.1016\/j.nurt.2008.09.001_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.nurt.2007.01.004","article-title":"Challenges in the design and conduct of therapeutic trials in channel disorders","volume":"4","author":"Venance","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2008.09.001_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1531-8249(200001)47:1<46::AID-ANA9>3.0.CO;2-H","article-title":"Randomized trials of dichlorphenamide in the periodic paralyses","volume":"47","author":"Tawil","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.09.001_bib7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1096\/fj.03-0722fje","article-title":"Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats","volume":"18","author":"Tricarico","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.nurt.2008.09.001_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archneur.1984.04050130041019","article-title":"Dissociation of glucose and potassium arterial-venous differences across the forearm by acetazolamide: a possible relationship to acetazolamide's beneficial effect in hypokalemia periodic paralysis","volume":"41","author":"Riggs","year":"1984","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.09.001_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1212\/WNL.31.6.725","article-title":"Acute effects of acetazolamide in hyperkalemic periodic paralysis and in normals","volume":"31","author":"Riggs","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.09.001_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/mus.880130513","article-title":"Enhancement of K+ conductance improves the in vitro contraction force of skeletal muscle in hypokalemic periodic paralysis","volume":"13","author":"Grafe","year":"1990","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0735-6757(03)00159-1","article-title":"A simple and rapid approach to hypokalemic paralysis","volume":"21","author":"Lin","year":"2003","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.nurt.2008.09.001_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1113\/jphysiol.1983.sp014552","article-title":"Barium-treated mammalian skeletal muscle: similarities to hypokalemic periodic paralysis","volume":"335","author":"Gallant","year":"1983","journal-title":"J Physiol"},{"key":"10.1016\/j.nurt.2008.09.001_bib13","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.53.7.1556","article-title":"Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current","volume":"53","author":"Ruff","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.09.001_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1096\/fj.05-5070com","article-title":"Phosphorylation and protonation of neighboring MiRP2 sites: function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis","volume":"20","author":"Abbot","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.nurt.2008.09.001_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1172\/JCI4552","article-title":"Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis","volume":"103","author":"Tricarico","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nurt.2008.09.001_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/hmg\/ddl181","article-title":"RNA-dominant diseases","volume":"15","author":"Osborne","year":"2006","journal-title":"Human Mol Genet"},{"key":"10.1016\/j.nurt.2008.09.001_bib17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/jphysiol.2001.012541","article-title":"Mexilitene block of disease-associated muations in S6 segments of the human skeletal muscle Na+ channel","volume":"537","author":"Takahashi","year":"2001","journal-title":"J Physiol"},{"key":"10.1016\/j.nurt.2008.09.001_bib18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/01.wnl.0000257825.29703.e8","article-title":"Efficacy of propafenone in paramytonia congenita","volume":"68","author":"Alfonsi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.09.001_bib19","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1046\/j.1528-1157.2003.58102.x-i1","article-title":"Nicotine as an anti-epileptic agent in ADNFLE: an n-of-one study","volume":"44","author":"Willoughby","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.nurt.2008.09.001_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0895-4356(96)00429-5","article-title":"Combining single patient (n-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment","volume":"50","author":"Zucker","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nurt.2008.09.001_bib21","first-page":"3952","article-title":"Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy","volume":"117","author":"Wheeler","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nurt.2008.09.001_bib22","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1172\/JCI200216481","article-title":"Functional repair of a mutant chloride channel using a trans-splicing ribozyme","volume":"110","author":"Rogers","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nurt.2008.09.001_bib23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1212\/01.wnl.0000267884.39468.7a","article-title":"Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase","volume":"69","author":"Argov","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.09.001_bib24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/mus.20865","article-title":"Muscle membrane excitability after exercise in thyrotoxic periodic paralysis and thyrotoxicosis without periodic paralysis","volume":"36","author":"Arimura","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1212\/WNL.54.4.937","article-title":"Functional consequence of chloride channel gene (CLCN1) mutations causing myotonia congenita","volume":"54","author":"Zhang","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.09.001_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/mus.20922","article-title":"F413C and A531V but not R894X myotonia congenita mutations cause defective endoplasmic reticulum export of the muscle-specific chloride channel CLC-1","volume":"37","author":"Papponen","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/mol.106.023994","article-title":"Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones","volume":"70","author":"Wang","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.nurt.2008.09.001_bib28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.nmd.2004.06.007","article-title":"Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia","volume":"14","author":"Kinali","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.09.001_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.20884","article-title":"Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy","volume":"37","author":"Allen","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib30","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000275523.95103.36","article-title":"Peripheral nerve hyperexcitability due to dominant negative KCNQ2 mutations","volume":"69","author":"Wuttke","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.09.001_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nurt.2007.01.005","article-title":"Management and treatment of Andersen-Tawil syndrome","volume":"4","author":"Sansone","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2008.09.001_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10072-005-0461-x","article-title":"Human skeletal muscle sodium channelopathies","volume":"26","author":"Vicart","year":"2005","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nurt.2008.09.001_bib33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ana.20511","article-title":"Erythromelalgia: a hereditary pain syndrome enters the molecular era","volume":"57","author":"Waxman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.09.001_bib34","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1073\/pnas.1230273100","article-title":"Myasthenic syndrome caused by mutation of the SCN4A channel","volume":"100","author":"Tsujino","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nurt.2008.09.001_bib35","series-title":"Myasthenia gravis and myasthenic disorders","first-page":"251","article-title":"Congenital myasthenic syndromes","author":"Engel","year":"1999"},{"key":"10.1016\/j.nurt.2008.09.001_bib36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.bbrc.2004.08.031","article-title":"Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease","volume":"322","author":"Lyfenko","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nurt.2008.09.001_bib37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/mus.10266","article-title":"Ion channel and striational antibodies define a continuum of autoimmune neuromuscular excitability","volume":"26","author":"Vernino","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.09.001_bib38","series-title":"Myasthenia Gravis and Related Disorders","first-page":"205","article-title":"The Lambert-Eaton myasthenic syndrome","author":"Newsom-Davis","year":"1999"},{"key":"10.1016\/j.nurt.2008.09.001_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10974-006-9074-5","article-title":"Dysregulation of sodium channel gating in critical illness myopathy","volume":"27","author":"Teener","year":"2006","journal-title":"J Muscle Res Cell Motil"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.09.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:38:27Z","timestamp":1761806307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923004683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1878747923004683"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.09.001","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Neuromuscular Channelopathies: Current Concepts and Future Prospects","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}